← Back to home

Previously untreated locally advanced (iiib/IIIC) or metastatic (IV) E NSQ NSCLC without actionable genomic alterations

Clinical trials for Previously untreated locally advanced (iiib/IIIC) or metastatic (IV) E NSQ NSCLC without actionable genomic alterations explained in plain language.

Never miss a new study

Get alerted when new Previously untreated locally advanced (iiib/IIIC) or metastatic (IV) E NSQ NSCLC without actionable genomic alterations trials appear

Sign up with your email to follow new studies for Previously untreated locally advanced (iiib/IIIC) or metastatic (IV) E NSQ NSCLC without actionable genomic alterations, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New antibody RC148 takes aim at lung cancer in Head-to-Head phase 3 trial

Disease control Not yet recruiting

Researchers are testing whether adding the experimental drug RC148 to platinum-based chemotherapy helps people with advanced non-squamous non-small cell lung cancer live longer without their disease worsening, compared with tislelizumab plus the same chemotherapy. The trial enrol…

Matched conditions: PREVIOUSLY UNTREATED LOCALLY ADVANCED (IIIB/IIIC) OR METASTATIC (IV) E NSQ NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS

Phase 3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control

Last updated Sep 22, 2026 02:00 UTC

Previously untreated locally advanced (iiib/IIIC) or metastatic (IV) E NSQ NSCLC without actionable genomic alterations

Get alerted when new Previously untreated locally advanced (iiib/IIIC) or metastatic (IV) E NSQ NSCLC without actionable genomic alterations trials appear

New antibody RC148 takes aim at lung cancer in Head-to-Head phase 3 trial